Targeted treatment regimens have significantly improved overall survival for patients with chronic lymphocytic leukemia (CLL). The emergence of new options such as BTK inhibitors has shifted the treatment landscape significantly, bringing a pressing need for education for providers, patients, and caregivers. This included a persistent need for:
- A better understanding of frontline treatment considerations
- Point-of-care clinical discussions
- Expert answers to patient questions
- Patient/provider alignment
Surveys found patients found it challenging to understand treatment options, with 67% reporting they were not familiar with BTK inhibitors. There were also gaps in understanding between patients and providers in numerous areas.
Over the past three years, the CLL Society and PlatformQ Health have teamed up to produce serial education. This digital education consisted of 11 programs hosted on CancerCoachLive.com and OMedLive.com, led by key opinion leaders from Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, and UCI Cancer Center. Thanks to branching technology, multimodal delivery, and case-based discussions, there was a high degree of engagement in the programs.
Program results were measured through polling held prior to, immediately following, and two months after each session. In total, there were 2,277 HCP learners and 795 certificates issued. On the patient side, there was 31,546 total engagement. Afterwards, 72% of patients reported that they were confident talking with their doctors and teams about treatment. The surveys also revealed key areas where there is low baseline provider knowledge, helping to inform the development of future programs.
The multi-year educational initiative has been successful at improving care as well as helping patients and providers to align around care. The survey data was shared at the 2022 ASH Annual Meeting to illustrate how a timelapse perspective can be used to uncover insights about the educational needs of patients and providers.
Download PlatformQ Health’s digital abstracts that were also accepted for inclusion at the 2022 ASH Annual Meeting: